P970: SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA

P970: SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Bibliographic Details
Main Authors:	Y. Wang, X. Hu, Q. Gao, H. Wang, Y. Gao, W. Zhang, X. Ru, L. Hou, W. Zhou, H. Zhang, Y. Zhang, F. Wang, X. Li, F. Guan
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846748.66048.bc

Similar Items

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)

P378: THE PROGNOSIS FACTORS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL
by: Y. Wang, et al.
Published: (2022-06-01)

P944: A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: X. Qu, et al.
Published: (2022-06-01)

P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA
by: Yi Wang, et al.
Published: (2023-08-01)

S187: UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A, FULLY HUMAN BCMA-DIRECTED CAR T CELLS, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
by: Wei Li, et al.
Published: (2023-05-01)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
by: Endeshaw Chekol Abebe, et al.
Published: (2022-09-01)

P1218: FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
by: X. Chen, et al.
Published: (2022-06-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
by: Yan Zhang, et al.
Published: (2022-09-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
by: James F. Wu, et al.
Published: (2023-07-01)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
by: Kai Rejeski, et al.
Published: (2023-07-01)

S186: UPDATED RESULTS OF A MULTICENTER FIRST-IN-HUMAN STUDY OF BCMA/CD19 DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: J. Du, et al.
Published: (2022-06-01)

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
by: N. Asherie, et al.
Published: (2022-06-01)

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
by: Ming Shi, et al.
Published: (2024-04-01)

S133: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
by: R. Huang, et al.
Published: (2022-06-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
by: Di Wang, et al.
Published: (2023-11-01)

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
by: David M. Foureau, et al.
Published: (2020-07-01)

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis
by: Han Xu, et al.
Published: (2024-04-01)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
by: Hila Magen, et al.
Published: (2023-08-01)

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
by: Hanley N. Abramson
Published: (2020-07-01)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01)

P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: D.E. Lowther, et al.
Published: (2023-05-01)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
by: Ross Firestone, et al.
Published: (2023-08-01)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
by: Jarrod Longcor, et al.
Published: (2022-09-01)

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
by: C. Touzeau, et al.
Published: (2022-06-01)

P953: PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: W. Tang, et al.
Published: (2022-06-01)

S103: EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: C. Fernandez De Larrea, et al.
Published: (2022-06-01)

PB1999: ATG-010 PLUS LOW-DOSE DEXAMETHASONE (SD) IN CHINESE RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS PREVIOUSLY RECEIVED CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T)
by: W. Fu, et al.
Published: (2022-06-01)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
by: Martin Vogel, et al.
Published: (2023-05-01)

Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
by: Dingyuan Hu, et al.
Published: (2023-06-01)

1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma
by: Henry Miles Prince, et al.
Published: (2023-11-01)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
by: Robert Berahovich, et al.
Published: (2018-09-01)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
by: Ting Wang, et al.
Published: (2022-05-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
by: Borja Puertas, et al.
Published: (2022-03-01)